Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity involves big bets across va...
Piper Sandler analyst David Amsellem reiterates Alkermes (NASDAQ:ALKS) with a Overweight and raises the price target from $3...
RBC Capital analyst Leonid Timashev maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $45 ...
Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicin...
Analysts' ratings for Alkermes (NASDAQ: ALKS) over the last quarter vary from bullish to bearish, as provided by 9 analysts...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
RBC Capital analyst Leonid Timashev upgrades Alkermes (NASDAQ: ALKS) from Sector Perform to Outperform and raises the price ...
